Bristol Myers Squibb Co 8-K, filed Nov 17, 2020
Bristol Myers Squibb Co (BMY)
8-K
2020-11-17
For: 2020-11-17
View Original
Added on
April 02, 2026
About this 8-K
Bristol Myers Squibb Co filed this 8-K on November 17, 2020.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act Of 1934
Date of Report (Date of earliest event reported): November 17, 2020
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
(State or Other Jurisdiction|
of Incorporation) |
(Commission
File Number) |
(IRS Employer
Identification Number) |
(Address of Principal Executive Office)
Registrant’s telephone number, including area code: (212 ) 546-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s) |
Name of each exchange
on which registered |
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 8.01.
|
Other Events.
|
On November 17, 2020, Bristol-Myers Squibb Company, a Delaware corporation (“Bristol Myers Squibb”), announced the completion of the acquisition of all of the
outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of MyoKardia, Inc., a Delaware corporation (“MyoKardia”). The acquisition of the Shares was structured as a two-step transaction, with a cash tender offer by Gotham
Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Bristol Myers Squibb (“Merger Sub”), for the Shares at a price of $225.00 per Share, net to the seller in cash (without interest) but subject to any required withholding taxes,
upon the terms and subject to the conditions set forth in the Offer to Purchase and the related Letter of Transmittal, each as amended and supplemented, filed by Bristol Myers Squibb and Merger Sub with the Securities and Exchange Commission (the
“SEC”) on October 19, 2020, followed by the merger of Merger Sub with and into MyoKardia. A copy of the press release announcing completion of the acquisition filed as Exhibit (a)(5)(xv) to
the Schedule TO-T/A filed by Bristol Myers Squibb with the SEC on November 17, 2020 is incorporated herein by reference as Exhibit 99.1.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
Exhibit
No. |
Description
|
|
|
99.1
|
Press Release of Bristol Myers Squibb, dated November 17, 2020 (incorporated by reference to Exhibit (a)(5)(xv) of the Schedule TO-T/A filed by Bristol Myers Squibb with
the SEC on November 17, 2020).
|
|
|
104
|
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
|
EXHIBIT INDEX
|
Exhibit
No. |
Description
|
|
|
Press Release of Bristol Myers Squibb, dated November 17, 2020 (incorporated by reference to Exhibit (a)(5)(xv) of the Schedule TO-T/A filed by Bristol Myers Squibb with
the SEC on November 17, 2020).
|
||
|
104
|
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
BRISTOL-MYERS SQUIBB COMPANY
|
||
|
Dated: November 17, 2020
|
By:
|
/s/ Katherine R. Kelly
|
|
Name:
|
Katherine R. Kelly
|
|
|
Title:
|
Corporate Secretary
|
|
3